Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

PHASE2TerminatedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

October 31, 2009

Conditions
Pancreatic Cancer
Interventions
DRUG

RP101

190 mg oral tablet

DRUG

Gemcitabine (1000 mg/m2)

30 minute intravenous infusion

Trial Locations (55)

18015

St. Luke's Cancer Center, Bethlehem

32256

Integrated Community Oncology Network, LLC, Jacksonville

33805

Lakeland Regional Cancer Center, Lakeland

44718

Gabrail Cancer Center, Canton

45042

Signal Point Clinical Research Center, LLC, Middletown

53226

Medical College of Wisconsin, Froedtert Multi-Disciplinary Cancer Center, Milwaukee

58501

Mid Dakota Clinic, Bismarck

77030

Baylor College of Medicine, Houston

78207

South Texas Oncology and Hematology, PA, San Antonio

84106

Utah Cancer Specialists, Salt Lake City

85724

University of Arizona Medical Center, Arizona Cancer Center, Tucson

90211

Tower Research Foundation at Tower Oncology, Beverly Hills

94110

University of California at San Francisco, San Francisco

97231

Providence Portland Medical Center, Portland

99202

Cancer Care Northwest, Spokane

98109-1023

University of Washington, Seattle

Unknown

Hospital Italiano Regional del Sur, Bahía Blanca

Hospital Británico de Buenos Aires, Ciudad Autónoma de Buenos Aires

Hospital Zonal General de Agudos San Roque, La Plata

Hospital de Caridade de Ijuí, Ijuí

Hospital de Clínicas de Porto Alegre, Serviço de Oncologia, Porto Alegre

Instituto Nacional do Câncer, Rio de Janeiro

Núcleo de Oncologia da Bahia, Salvador

Hospital do Câncer-AC Camargo, São Paulo

Fundación Arturo López Pérez, Santiago

Hospital Militar, Santiago

Hôpital Gabriel Montpied, Clermont-Ferrand

Centre Hospitalier Départemental, La Roche-sur-Yon

Centre Eugene Marquis, Service d'Oncologie Medicale, Rennes

Universitätsklinikum Dresden, Med. Klinik I, Dresden

Klinikum Region Hannover GmbH, Krankenhause Siloah, Hanover

Klinikum rechts der Isar, Technische Universität München, München

Petz Aladár Megyei Oktató Kórház Orvostovábbképzo Egyetem Oktató-Továbbképzo Kórháza, Onkoradiológia, Gyor

Fovárosi Önkormányzat Egyesített Szent István és Szent László Kórház-Rendelointézet, Budapest

Fovárosi Önkormányzat Uzsoki utcai Kórháza, Budapest

Debreceni Egyetem Orvos és Egészségtudományi Centrum, Onkológiai Tanszék, Debrecen

Maaslandziekenhuis, Sittard

Hospital Nacional Guillermo Almenara Irigoyen, La Victoria

Hospital Nacional Edgardo Rebagliati Martins, Lima

Instituto Oncocenter, San Borja

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Wojewódzki, Jelenia Góra

I Katedra Chirurgii Ogólnej i Klinika Chirurgii Gastroenterologicznej, Krakow

Wojewódzki Szpital Specjalistyczny im Kopernika w Lodzi, Lódz

Centrum Medyczne MRUKMED, Rzeszów

Institutul Clinic Fundeni, Bucharest

Institutul Oncologic 'Prof. Dr. A. Trestioreanu', Bucharest

Spitalul Clinic de Urgenta Floreasca, Bucharest

Spitalul Clinic Universitar de Urgenta, Bucharest

Hospital Universitario Arnau de Vilanova, Servicio de Oncologia, Lleida

Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-San Chinarro, Madrid

Hospital 12 de Octubre, Oncology Service, Hospital Materno Infantil, Madrid

Instituto Valenciano de Oncología, Valencia

Hospital Universitario Miguel Servet, Zaragoza

Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester

Mount Vernon Hospital, Middlesex

Sponsors
All Listed Sponsors
lead

SciClone Pharmaceuticals

INDUSTRY